The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs in an attempt to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. According to UNAIDS, there were approximately 36.7 million people worldwide living with HIV/AIDS at the end of 2015, whereas 18.2 million people living with HIV were accessing antiretroviral therapy (ART) globally. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient’s total burden of HIV, maintains function of the immune system, and prevents opportunistic infections. There are six classes of drugs, which are usually used in combination, to treat HIV infection. Antiretroviral (ARV) drugs are broadly classified by the phase of the retrovirus life-cycle that the drug inhibits. Typical combinations include 2 NRTIs as a “backbone” along with 1 NNRTI, PI or INSTI as a “base.” The current standard of care for treatment naïve HIV-positive patients is triple therapy composed of two nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent from a different class: either an integrase strand transfer inhibitor (InSTI) or a boosted protease inhibitor (BPI). Most regimens are available in fixed-dose combinations (FDCs) or single-tablet regimens (STRs). Potent combination antiretroviral therapy (ART), typically consisting of three or more antiretroviral (ARV) drugs, has greatly improved the health and survival rates of HIV-infected patients in areas of the world with access to ARVs. Combinations of antiretrovirals are subject to positive and negative synergies, which limits the number of useful combinations.
The global HIV therapy market segmentation is based on drug class – nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (InSTIs), protease inhibitors (PIs), others; and drug brands (Atripla, Complera, Isentress, Prezista, Stribild, Triumeq/Tivicay, Truvada, Viread, Others).
The global HIV therapy market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global HIV therapy market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global HIV therapy market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global HIV therapy market and profiled in this report include AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck & Co., and ViiV Healthcare.